Business
TME Pharma Publishes 2024 Financial Results and Provides Operating Update
BERLIN, April 25, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update.
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/c25b60ff83ad5d7c97039d49700bc86d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/irTfd4SEwqjMZd5Cf7luVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c25b60ff83ad5d7c97039d49700bc86d","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/x6bODbtq8OKT_PEozXKBXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c25b60ff83ad5d7c97039d49700bc86d","width":1000,"height":313}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total €7.6 million raised through multiple transactions","length":55,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"All convertible debt instruments removed from balance sheet during 2024","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Commitment to lean cost structure while focusing on completing strategic goals","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Next clinical development steps for NOX-A12 validated by regulators","length":67,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pursuit of several transaction structures in parallel for the company’s drug candidates","length":87,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":358,"olType":false},{"type":"text","content":"BERLIN, April 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":57,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update.","length":311,"tagName":"p"},{"type":"text","content":"The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma’s website (www.tmepharma.com).","length":153,"tagName":"p"},{"type":"text","content":""TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as ...